BiotechTube
Progen Biotechnik

Progen Biotechnik

Heidelberg, Germany· Est.
progen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500K

Overview

Progen Biotechnik is a long-established, privately held German company that serves as a critical enabler for the gene therapy industry by providing essential analytical reagents and tools. Its core focus is on AAV vector characterization, offering validated, off-the-shelf products for capsid titer determination, empty/full capsid analysis, and immunogenicity assessment. With a strong reputation for reliability, scientific support, and global distribution, PROGEN positions itself as a trusted partner for academic, biotech, and pharmaceutical researchers advancing gene and cell therapies.

Antibodies

Technology Platform

Immunoassay and antibody-based analytical platforms for viral vector (AAV, LVV) and LNP characterization, including ELISA kits, monoclonal/polyclonal antibodies, reference standards, and density gradient media.

Funding History

1
Total raised:$500K
Grant$500K

Opportunities

The rapid growth of the gene therapy market, with thousands of therapies in development, creates sustained demand for reliable analytical tools.
Expansion into adjacent high-growth areas like lentiviral vectors and lipid nanoparticles (LNPs) provides significant new revenue streams and diversifies the company's market exposure.

Risk Factors

Heavy reliance on the continued success of AAV-based therapies exposes the company to sector-specific clinical or regulatory setbacks.
Intense competition from larger, well-capitalized life science tools companies poses a constant threat to market share and pricing power.

Competitive Landscape

PROGEN competes in the niche of specialized gene therapy analytical tools against larger, diversified life science suppliers like Sartorius, Thermo Fisher Scientific, and Bio-Techne. Its competitive advantage lies in deep AAV-specific expertise, a focused product portfolio, high-quality antibodies, and direct scientific support, but it faces constant pressure from competitors with broader commercial reach and resources.

More companies in Cell & Gene Therapy →More companies in Germany →